Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 1, Issue 11, Pages e44-e44
Publisher
Springer Nature
Online
2011-11-11
DOI
10.1038/bcj.2011.43
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
- (2011) M. Levis et al. BLOOD
- FLT3 inhibitors: a story of the old and the new
- (2011) Amir Fathi et al. CURRENT OPINION IN HEMATOLOGY
- Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia
- (2011) Takayuki Ikezoe et al. INTERNATIONAL JOURNAL OF CANCER
- Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma
- (2011) Anthony D. William et al. JOURNAL OF MEDICINAL CHEMISTRY
- FLT3 as a therapeutic target in AML: still challenging after all these years
- (2010) T. Kindler et al. BLOOD
- JAK2 inhibitors: What's the true therapeutic potential?
- (2010) Fabio P.S. Santos et al. BLOOD REVIEWS
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Inhibition of signal transducer and activator of transcription 5 by the inhibitor of janus kinases stimulates dormant human leukemia CD34+/CD38− cells and sensitizes them to antileukemia agents
- (2010) Takayuki Ikezoe et al. INTERNATIONAL JOURNAL OF CANCER
- Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
- (2010) Thomas Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer
- (2010) V. Novotny-Diermayr et al. MOLECULAR CANCER THERAPEUTICS
- Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML
- (2009) J. Zhou et al. BLOOD
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
- Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells
- (2009) Liqing Jin et al. Cell Stem Cell
- FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML
- (2009) Ellen Weisberg et al. DRUG RESISTANCE UPDATES
- A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response
- (2008) K. W. Pratz et al. BLOOD
- Effects of the JAK2 Inhibitor, AZ960, on Pim/BAD/BCL-xL Survival Signaling in the Human JAK2 V617F Cell Line SET-2
- (2008) Joseph M. Gozgit et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now